Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow Transplantation

Blood
Alexander ClaviezLymphoma and Pediatric Diseases Working Parties

Abstract

Ninety-one children and adolescents 18 years or younger after allogeneic hematopoietic stem cell transplantation (HSCT) for relapsed or refractory Hodgkin lymphoma (HL) were analyzed. Fifty-one patients received reduced intensity conditioning (RIC); 40 patients received myeloablative conditioning (MAC). Nonrelapse mortality (NRM) at 1 year was 21% (+/- 4%), with comparable results after RIC or MAC. Probabilities of relapse at 2 and 5 years were 36% (+/- 5%) and 44% (+/- 6%), respectively. RIC was associated with an increased relapse risk compared with MAC; most apparent beginning 9 months after HSCT (P = .01). Progression-free survival (PFS) was 40% (+/- 6%) and 30% (+/- 6%) and overall survival (OS) was 54% (+/- 6%) and 45% (+/- 6%) at 2 and 5 years, respectively. Disease status at HSCT was predictive of PFS in multivariate analysis (P < .001). Beyond 9 months, PFS after RIC was lower compared with MAC (P = .02). Graft-versus-host disease did not affect relapse rate and PFS. In conclusion, children and adolescents with recurring HL show reasonable results with allogeneic HSCT. Especially patients allografted in recent years with good performance status and chemosensitive disease show highly encouraging results (PFS: 60% +/- 27...Continue Reading

References

Nov 1, 1985·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F R AppelbaumR Storb
Aug 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G L PhillipsS N Wolff
Dec 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J E AndersonJ E Sanders
Feb 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J GajewskiMary M Horowitz
Apr 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N MilpiedAnthony H Goldstone
Nov 30, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Günther SchellongE W Schwarze
Feb 24, 2001·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·J FrankovichM R Verneris
Dec 4, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gorgun AkpekR J Jones
Feb 16, 2002·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Stephanie J LeePaul J Martin
Jun 25, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K M KellyChildren's Oncology Group
Sep 14, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James B NachmanChildren's Cancer Group
Nov 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·YeeYie E LieskovskyRajni Agarwal
Sep 2, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Günther SchellongDAL/GPOH
Jan 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sarah S DonaldsonMelissa M Hudson

Citations

Oct 20, 2012·Current Opinion in Oncology·Anna SuredaLymphoma Working Party of the European Group for Blood and Marrow Transplantation
Sep 5, 2009·Blood·James B Nachman
Dec 8, 2009·Blood·Norbert SchmitzLymphoma and Pediatric Diseases Working Parties
Mar 29, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anas YounesRobert Chen
Apr 23, 2014·Current Treatment Options in Oncology·Anna SuredaLymphoma Working Party of the European Group for Stem Cell Transplantation
Dec 2, 2014·Pediatric Clinics of North America·Kanwaldeep MallhiMaxim Yankelevich
Dec 16, 2011·Leukemia & Lymphoma·Dennis A EichenauerAndreas Engert
Apr 17, 2013·Expert Opinion on Biological Therapy·Tiziana MoscatoMassimo Martino
Oct 23, 2012·Cancer radiothérapie : journal de la Société française de radiothérapie oncologique·L KochbatiM Maalej
Jan 21, 2016·Journal of Immunology Research·Roberta FedeleFortunato Morabito
Dec 8, 2010·British Journal of Haematology·Stephen DawHamish Wallace
Dec 23, 2011·British Journal of Haematology·Kara M Kelly
Mar 13, 2014·Pediatric Blood & Cancer·Stephanie A TerezakisLouis S Constine
Oct 15, 2013·British Journal of Haematology·Graham P CollinsKarl S Peggs
Mar 17, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Miguel-Angel PeralesPaul A Carpenter
Oct 29, 2010·Advances in Hematology·Evgeny KlyuchnikovAxel Rolf Zander
Oct 18, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·M S CairoJohn Pagel
Dec 21, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·P SatwaniM S Cairo
Jul 20, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Richard E HarrisM S Cairo
Mar 8, 2013·Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie·J-H Dalle
Mar 29, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Yong-Xian HuHe Huang
Feb 2, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Karl S PeggsStephen Mackinnon
Apr 4, 2017·Bone Marrow Transplantation·M A Kharfan-DabajaM Hamadani
Apr 1, 2011·Therapeutic Advances in Hematology·James K Mangan, Selina M Luger
Mar 11, 2010·Expert Review of Anticancer Therapy·Niels MurawskiMichael Pfreundschuh
Sep 14, 2012·Expert Opinion on Pharmacotherapy·Katarzyna Jamieson, Olatoyosi Odenike
Jun 20, 2014·Journal of Clinical and Experimental Hematopathology : JCEH·Sung Won Kim
Nov 12, 2017·Paediatric Drugs·Christine Mauz-KörholzDieter Körholz

Related Concepts

Graft-vs-Host Disease
Hodgkin Lymphoma, Lymphocyte Depletion
Relapse
Transplantation, Homologous
Hemopoietic Stem Cell Transplant
Progression-Free Survival
Transplantation Conditioning
Blood
Bone Marrow Transplantation
Graft-vs-Host Disease

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.